Navigation Links
Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
Date:7/21/2009

MOUNTAIN VIEW, Calif., July 21 /PRNewswire/ -- Howard Rosenberg, M.D., a board-certified plastic surgeon and Medical Director at Accent on Aesthetics Plastic Surgery Medical Center, has selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines. Dr. Rosenberg has treated more than fifty patients with Artefill due to its proven success and effectiveness for the long lasting correction of wrinkles.

Dr. Rosenberg commented, "Artefill is a product we have consistently recommended to our patients who are looking for a dermal filler that lasts longer and doesn't require repeat injections. We believe we have had great success with the product over the past few years as it's easy to administer and the patient experience is similar to temporary fillers on the market today."

This simple, in-office procedure takes approximately fifteen minutes to complete. A patient is injected with Artefill similar to other dermal fillers with the key difference being its lasting effect. The unique microspheres in Artefill are not absorbed by the body and therefore provide the support the skin needs for long lasting natural feeling results. This is different from temporary dermal fillers that are made of different kinds of natural or synthetic materials that are completely absorbed by the body over time and require repeat injections to maintain wrinkle correction. A skin test is required prior to treatment or approximately four (4) weeks ahead of time, to ensure a patient is not allergic to the collagen or anesthetic in Artefill.

Artefill is only offered by a select group of physicians in Northern California and is not available at all physician offices. Dr. Rosenberg is one of the company trained and select few company sponsored physicians who has the skills and experience needed to administer the product.

Stephanie C., a patient of Dr. Rosenberg's said, "I am delighted with the results of Artefill that I just received and will be returning for even more."

About Artefill:

Artefill is the first and only FDA-approved microsphere-enhanced collagen filler for the correction of nasolabial folds, better known as smile lines. The safety and effectiveness of Artefill has been extensively studied over the past eight years. Since Artefill was approved in 2006, over 10 thousand patients have been treated successfully with very high satisfaction rates.

Suneva Medical, Inc., a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets, markets and manufactures Artefill. The Company was formed in April 2009 to deliver the same great product that physicians and patients have embraced over the past several years. For more information visit www.artefill.com or www.sunevamedical.com.

About Accent on Aesthetics Plastic Surgery Medical Center:

As Medical Director of Accent on Aesthetics Plastic Surgery Medical Center, Dr. Howard L. Rosenberg is one of the Bay Area's most sought-after experts on cosmetic enhancement. With over two decades of experience, Dr. Rosenberg offers a comprehensive menu of the most advanced surgical and noninvasive procedures available. You can feel confident you have chosen a doctor who can give you the beautiful, natural-looking results you want. You'll also appreciate his warmth and sensitivity - with Dr. Rosenberg as your doctor, you will always feel valued, appreciated and well cared for. For more information visit http://www.accentonaesthetics.com/.

ATTENTION MEDIA: To download Artefill patient before and after pictures visit http://www.artefill.com/content/c/beforeandafter/overview.asp.

    Contact:
    Dr. Howard L. Rosenberg, MD, FACS
    Accent on Aesthetics Plastic Surgery Medical Center
    650-961-2652


'/>"/>
SOURCE Accent on Aesthetics Plastic Surgery Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
2. New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults
3. Plastic Surgeons Warn of Malnutrition in Body Contouring Patients
4. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
6. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
7. Got Fat?: Plastic Surgeons Review Fat-Melting and Fat-Grafting Procedures
8. Miami Plastic Surgeon Offers Hope to Acne Scarred Patients
9. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Shoulder Surgery Doesnt Prevent Return to Sports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 According to ... entitled "Brain Computer Interface Market - Global Industry Analysis, Size, ... brain computer interface (BCI) market  is expected to reach ... is estimated to expand at a CAGR of 14.9 ... A BCI device provides collaboration between the ...
(Date:5/4/2016)... 4, 2016 According to market research ... Demand Forecast to 2022 - Industry Insights by Slice Type ... and Others)" by P&S Market Research, the global computed ... and it is expected to grow at a CAGR of ... type segment is expected to witness the faster growth, CAGR ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... The ... is slated to host the 2016 National SACA Leadership Conference on the Portland ... officers and chapter officers to come together and develop skills to be future ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... ... 2016 , ... In order to increase comfort, convenience and ... Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , a new ... app, developed for both smartphones and personal computers perfectly emulates that of the ...
(Date:5/5/2016)... Ohio (PRWEB) , ... May 05, 2016 , ... United ... Cycle. , Clark brings more than 15 years of experience within the healthcare ... from a successful career as the Director of Patient Financial Services at Spectrum Health. ...
(Date:5/5/2016)... ... 2016 , ... CURE Media Group , the nation’s leading digital and ... Imerman Angels to expand outreach and emotional support for patients of all ... an emotional lifeline to patients and families facing the challenges of cancer diagnosis and ...
Breaking Medicine News(10 mins):